Actively Recruiting
Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing Eosinophils
Led by Medical University Innsbruck · Updated on 2020-09-04
300
Participants Needed
1
Research Sites
469 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting a prospective registry study to better understand eosinophilic lung diseases, such as eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), Samter Triad, hypereosinophilic syndrome (HES), and eosinophilic pneumonia. These conditions can affect the lungs alone or be part of systemic diseases, and their causes and treatments are not yet fully understood. The study aims to explore different subtypes of eosinophils and their roles in these respiratory conditions, including the relationship between blood eosinophil levels and organ damage risk. This observational study includes patients who have eosinophilia with respiratory involvement and are diagnosed with the specified diseases. It includes patients switching from doctor-administered injections of the anti-IL5 antibody mepolizumab to self-injection pens. Special attention is given to patients with Samter Triad, monitoring asthma control, nasal polyps, and NSAID intolerance. The study also investigates whether some severe cases represent a clonal lymphoid HES by analyzing chemokines, mutations, and cell markers. Advanced laboratory techniques are used to characterize eosinophil subtypes in patients and healthy controls. Participants will provide consent to join the registry, and their medical data including laboratory tests, lung function, imaging, biopsies, and allergology findings will be collected over time during routine care. Additional blood samples are taken during regular blood draws for research purposes without extra risk. Healthy volunteers also provide blood samples for comparison. The main outcomes include establishing the registry with detailed disease and therapy data over 10 years and identifying eosinophil subtypes in peripheral blood within one year. There are no additional risks beyond standard care for participants.
CONDITIONS
Brief Title
Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing Eosinophils
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Documented blood eosinophilia of at least 300 cells per microliter
- Presence of tissue damage in the respiratory tract caused by eosinophils
You will not qualify if you...
- Under 18 years of age
- Pregnancy
- Dementia
- Patients unable to make their own decisions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 10 years
Participants are observed over time to collect data on eosinophilia with respiratory manifestations and to characterize eosinophils.
Trial Site Locations
Total: 1 location
1
University Clinic for Internal Medicine II
Innsbruck, Austria, 6020
Actively Recruiting
Research Team
I
Ivan Tancevski, MD
J
Judith Löffler-Ragg
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here